Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety and Effectiveness of REGN7075 and Cemiplimab, with or without Chemotherapy, for Patients with Advanced Solid Tumors

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying advanced forms of cancer, specifically solid tumors, which are abnormal masses of tissue that usually do not contain cysts or liquid areas. The study is investigating the safety and effectiveness of a new treatment combination. The treatment involves a medication called REGN7075, which is a type of protein designed to help the immune system fight cancer, used in combination with another medication called cemiplimab. Cemiplimab is an existing treatment that helps the immune system recognize and attack cancer cells. The study will also explore the effects of adding chemotherapy, which is a type of cancer treatment that uses drugs to destroy cancer cells, to this combination in certain cases.

The purpose of the study is to understand how safe and tolerable the combination of REGN7075 and cemiplimab is for patients with advanced solid tumors. The study will begin with a phase where the doses of the medications are gradually increased to find the safest dose that can be given without causing severe side effects. After this, the study will expand to include more patients to see how well the treatment works in different types of solid tumors. Throughout the study, researchers will monitor the patients for any side effects and measure how the cancer responds to the treatment.

Participants in the study will receive the medications through an infusion, which means the drugs are given directly into the bloodstream through a vein. The study will take place over several years, with the aim of gathering enough information to determine the best way to use these medications together. The ultimate goal is to find a treatment that is both safe and effective for people with advanced solid tumors, potentially offering a new option for those who have not responded well to other treatments.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes reviewing medical history and performing necessary tests to ensure the patient meets the study criteria.

    The patient must have a confirmed diagnosis of advanced solid tumors and meet other specific health criteria.

  2. Step 2

    Dose escalation phase

    In this phase, the patient receives a medication called REGN7075 as a lead-in treatment. This is administered as a solution for injection.

    Following the lead-in, REGN7075 is combined with another medication, cemiplimab, which is given as a solution for infusion. The purpose is to determine the safe dosage levels.

  3. Step 3

    Monitoring and evaluation

    Throughout the trial, the patient is closely monitored for any side effects or adverse reactions. Regular blood tests and health assessments are conducted to ensure safety.

    The patient's response to the treatment is evaluated using specific criteria to measure the effectiveness of the medication.

  4. Step 4

    Dose expansion phase

    In this phase, the patient may receive REGN7075 and cemiplimab with or without additional chemotherapy, depending on the specific cohort they are assigned to.

    The goal is to further assess the effectiveness of the treatment in a larger group of patients.

  5. Step 5

    Follow-up

    After completing the treatment phases, the patient enters a follow-up period where their health and response to the treatment are continuously monitored.

    This phase helps gather long-term data on the safety and effectiveness of the treatment.

Who can join the trial?

8 criteria

  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, which means the patient is fully active or has some symptoms but can carry out light work.
  • Has cancer confirmed by a doctor through tests like a biopsy, which involves taking a small sample of tissue for examination.
  • For certain groups in the study: Has never been treated with drugs targeting PD-1/PD-L1, which are proteins involved in the immune system's response to cancer.
  • Has at least one tumor that meets the study's specific requirements.
  • Is willing to provide a sample of tumor tissue from a new biopsy, which is a procedure to remove a small piece of tissue for testing, from a tumor that has not been treated with radiation before.
  • Has organs and bone marrow that are working well enough, as determined by the study's guidelines.
  • In the opinion of the study doctor, has a life expectancy of at least 3 months.
  • Is within the age range specified by the study, which includes both male and female participants.

Who cannot join the trial?

10 criteria

  • Patients who have a different type of cancer than the ones being studied, which are called solid tumors.
  • Patients who are not within the specified age range for the study.
  • Patients who are not able to understand or follow the study procedures.
  • Patients who have other serious health conditions that might interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who have participated in another clinical trial recently.
  • Patients who have allergies to the study medications or their ingredients.
  • Patients who are taking medications that might interfere with the study treatment.
  • Patients who have had a recent surgery or are planning to have surgery during the study.
  • Patients who have an active infection that requires treatment.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • REGN7075

    is a special type of medication called a bispecific antibody. It is designed to help the body's immune system fight cancer by targeting specific proteins found on cancer cells. In this trial, REGN7075 is being tested to see how safe it is and how well it works when used alone or in combination with another medication. The goal is to see if it can help treat advanced solid tumors, which are types of cancer that form in solid organs or tissues.

  • Cemiplimab

    is a medication that helps the immune system attack cancer cells. It works by blocking a protein that usually stops the immune system from working properly. By blocking this protein, cemiplimab can help the immune system find and destroy cancer cells more effectively. In this trial, cemiplimab is being used in combination with REGN7075 to see if the two medications together can better treat advanced solid tumors.

What is already known about the treatment

  • REGN7075

    REGN7075 is administered as an injection and is currently being studied in clinical trials for its potential use in treating advanced solid tumors. It is a bispecific antibody designed to engage the immune system by targeting two proteins, EGFR and CD28, to help the body fight cancer cells more effectively. This medication is still under investigation, and its safety and effectiveness are being evaluated in combination with another drug called cemiplimab. REGN7075 falls under the pharmacological classification of immunotherapy, which aims to boost the body's natural defenses to combat cancer.

  • Cemiplimab

    Cemiplimab is given as an injection and is already approved for use in certain types of cancer, but it is being further studied in combination with REGN7075 for advanced solid tumors. It works by blocking a protein called PD-1, which can help the immune system recognize and attack cancer cells. This medication is part of a class of drugs known as immune checkpoint inhibitors, which are designed to enhance the body's immune response against cancer.

Investigated diseases

Solid Tumors – Solid tumors are abnormal masses of tissue that usually do not contain cysts or liquid areas. They can occur in various parts of the body, including organs and bones. These tumors are characterized by the uncontrolled growth of cells that form a solid mass. As they progress, they can invade nearby tissues and organs, potentially causing functional impairments. The growth rate and behavior of solid tumors can vary widely depending on their type and location. Over time, they may spread to other parts of the body through the bloodstream or lymphatic system.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase I/IITrial ID2022-501234-37-00Protocol codeR7075-ONC-2009Estimated enrolment627 patientsSponsorRegeneron Pharmaceuticals Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.